Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTHNASDAQ:LUCDNASDAQ:PDEXNASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$13.85-2.2%$14.43$7.17▼$18.23$482.34M0.95390,525 shs699,443 shsLUCDLucid Diagnostics$1.26$1.28$0.71▼$1.80$136.32M1.31603,797 shs3.05 million shsPDEXPro-Dex$40.54-0.7%$48.49$16.84▼$70.26$132.20M0.1732,543 shs19,842 shsSTIMNeuronetics$3.46+2.4%$4.03$0.52▼$5.92$227.74M1.92778,881 shs1.06 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems0.00%-9.71%-14.24%+0.95%+81.28%LUCDLucid Diagnostics0.00%-2.33%-5.26%-17.11%+74.54%PDEXPro-Dex0.00%+2.48%-11.14%-17.13%+113.93%STIMNeuronetics0.00%-8.71%-13.28%-28.81%+90.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems3.5682 of 5 stars3.55.00.00.03.22.50.6LUCDLucid Diagnostics3.4753 of 5 stars3.65.00.00.03.21.70.6PDEXPro-Dex3.2542 of 5 stars3.52.00.00.02.22.51.9STIMNeuronetics2.3403 of 5 stars3.32.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 3.00Buy$24.0073.29% UpsideLUCDLucid Diagnostics 3.20Buy$3.55181.75% UpsidePDEXPro-Dex 3.00Buy$56.0038.14% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5058.96% UpsideCurrent Analyst Ratings BreakdownLatest LUCD, PDEX, STIM, and DCTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.50 ➝ $7.755/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/26/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.003/25/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/24/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.50 ➝ $3.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$37.21M12.96N/AN/A$2.15 per share6.44LUCDLucid Diagnostics$4.35M31.34N/AN/A($0.78) per share-1.62PDEXPro-Dex$53.84M2.45$0.96 per share42.34$9.03 per share4.49STIMNeuronetics$74.89M3.04N/AN/A$0.57 per share6.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/4/2025 (Estimated)LUCDLucid Diagnostics-$45.53M-$1.34N/AN/AN/A-1,699.86%N/A-124.27%8/11/2025 (Estimated)PDEXPro-Dex$2.13M$2.8014.4819.68N/A14.61%29.08%16.19%9/4/2025 (Estimated)STIMNeuronetics-$43.71M-$1.31N/AN/AN/A-53.67%-174.15%-38.41%8/11/2025 (Estimated)Latest LUCD, PDEX, STIM, and DCTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/6/2025Q1 2025STIMNeuronetics-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 million5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A15.9514.61LUCDLucid DiagnosticsN/A0.750.74PDEXPro-Dex0.282.731.45STIMNeuronetics1.402.442.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%LUCDLucid Diagnostics74.01%PDEXPro-Dex15.28%STIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.40%LUCDLucid Diagnostics6.80%PDEXPro-Dex47.50%STIMNeuronetics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.83 million28.77 millionOptionableLUCDLucid Diagnostics70108.19 million100.83 millionNo DataPDEXPro-Dex1403.26 million1.71 millionNot OptionableSTIMNeuronetics18065.82 million60.09 millionOptionableLUCD, PDEX, STIM, and DCTH HeadlinesRecent News About These CompaniesAssenagon Asset Management S.A. Acquires Shares of 97,656 Neuronetics, Inc. (NASDAQ:STIM)June 20 at 3:44 AM | marketbeat.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 19 at 7:00 PM | globenewswire.comNeuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial ProgramJune 10, 2025 | globenewswire.comNeuronetics, Inc. to Join Russell 3000® and Russell 2000® Indexes Effective June 30, 2025June 3, 2025 | nasdaq.comNeuronetics to join Russell 3000 and Russell 2000 indexesJune 2, 2025 | msn.comNeuronetics Set to Join Russell 2000® and Russell 3000® IndexesJune 2, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) Short Interest Down 26.2% in MayJune 2, 2025 | marketbeat.comNeuronetics, Inc. (NASDAQ:STIM) EVP Sells $826,074.20 in StockMay 15, 2025 | insidertrades.comNeuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness MonthMay 14, 2025 | tmcnet.comNeuronetics Announces Inducement Awards for New Team MembersMay 10, 2025 | msn.comNeuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83May 9, 2025 | finance.yahoo.comEarnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%May 7, 2025 | investing.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin ChallengesMay 7, 2025 | finance.yahoo.comNeuronetics, Inc. (STIM) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comNeuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comNeuronetics Reports First Quarter 2025 Financial and Operating ResultsMay 6, 2025 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 5, 2025 | globenewswire.comWhy Neuronetics, Inc. (STIM) is Surging in 2025April 30, 2025 | msn.comNeuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6April 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWorkday Stock Price Implosion: An Automatic Buy for AI InvestorsBy Thomas Hughes | May 26, 2025View Workday Stock Price Implosion: An Automatic Buy for AI InvestorsGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayWhy Analysts Are Bullish on Celsius Stock After 30% DropBy Gabriel Osorio-Mazilli | June 16, 2025View Why Analysts Are Bullish on Celsius Stock After 30% DropBroadcom Slides on Solid Earnings, AI Outlook Still StrongBy Leo Miller | June 6, 2025View Broadcom Slides on Solid Earnings, AI Outlook Still StrongLUCD, PDEX, STIM, and DCTH Company DescriptionsDelcath Systems NASDAQ:DCTH$13.85 -0.31 (-2.19%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$14.45 +0.60 (+4.33%) As of 06/20/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Lucid Diagnostics NASDAQ:LUCD$1.26 0.00 (0.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 06/20/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pro-Dex NASDAQ:PDEX$40.54 -0.30 (-0.73%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$40.55 +0.01 (+0.02%) As of 06/20/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Neuronetics NASDAQ:STIM$3.46 +0.08 (+2.37%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.67 +0.21 (+6.04%) As of 06/20/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
